相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Medicine, General & Internal
Ruben Rose et al.
Summary: This study compared the humoral immune response after heterologous vaccination with a SARS-CoV-2 vector vaccine and mRNA vaccine, and the antibody response after homologous vaccination schemes. The study found that heterologous vaccination resulted in a strong antibody response comparable to that of a homologous BNT162b2 vaccination scheme, indicating the development of a robust humoral immunity. However, for the delta variant, a reduction in neutralizing efficacy was observed in some participants.
Article
Medicine, General & Internal
Sue Ann Costa Clemens et al.
Summary: A study was conducted to evaluate the safety and immunogenicity of a third dose of heterologous or homologous vaccines in Brazilian adults who had previously received two doses of CoronaVac. The results showed that a third dose of heterologous vaccines (recombinant adenoviral vectored vaccine or mRNA vaccine) significantly increased immune responses and could improve protection against infection.
Article
Medicine, General & Internal
Arabella S. Stuart et al.
Summary: The study investigated the mixed use of different COVID-19 vaccines within the same schedule, showing that in certain conditions, heterologous vaccination can achieve similar immunogenicity to homologous vaccination, facilitating rapid global vaccine deployment.
News Item
Multidisciplinary Sciences
Heidi Ledford
Article
Biochemistry & Molecular Biology
Samuel M. S. Cheng et al.
Summary: Specific antibody levels against the SARS-CoV-2 Omicron variant decrease significantly after two doses of BNT162b2 or CoronaVac vaccines, but can be markedly increased with a booster dose of BNT162b2. Individuals who previously received two doses of BNT162b2 or CoronaVac showed reduced serum antibody titers against Omicron, while a BNT162b2 booster dose increased the antibody levels in the majority of individuals. This suggests mRNA vaccine boosters may be necessary in countries primarily using CoronaVac vaccines to combat the spread of Omicron.
Article
Biochemistry & Molecular Biology
Eddy Perez-Then et al.
Summary: The study found that a BNT162b2 mRNA vaccine booster can enhance neutralizing antibodies against the Omicron variant in individuals who received two doses of the CoronaVac vaccine, but antibody titers remain lower compared to the ancestral virus and the Delta variant.
Article
Medicine, General & Internal
R. L. Atmar et al.
Summary: This study investigated the efficacy of homologous and heterologous booster vaccines in adults who had completed a primary Covid-19 vaccine regimen. The results showed that both types of booster vaccines were safe and immunogenic.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Microbiology
Addi J. Romero-Olmedo et al.
Summary: After receiving two doses of BNT162b2, older adults generally exhibit lower antibody and T-cell responses compared to a younger control group. However, a third vaccination with BNT162b2 can boost these responses, with 4 out of 5 older adults who were previously low-/non-responders showing improved immune responses post third vaccination.
NATURE MICROBIOLOGY
(2022)
Article
Medicine, General & Internal
Ruediger Gross et al.
Summary: According to a study on a cohort of individuals who received heterologous ChAdOx1 nCoV-19 BNT162b2 vaccination, the regimen induced potent humoral and cellular immune responses, with strong neutralization of the most prevalent SARS-CoV-2 variants. The results suggest that this heterologous vaccination regimen is at least as immunogenic and protective as homologous vaccinations and also offers protection against current variants of concern.
Article
Immunology
Corine H. GeurtsvanKessel et al.
Summary: This study demonstrates that vaccinated individuals retain T cell immunity to the SARS-CoV-2 Omicron variant, despite low levels of neutralizing antibodies. Booster vaccinations can partially restore cross-neutralization of the Omicron variant.
SCIENCE IMMUNOLOGY
(2022)
Article
Immunology
Beomki Lee et al.
Summary: In this study, the performance and correlation of four immunoassay methods for SARS-CoV-2 antibody detection were evaluated. Three chemiluminescent assays showed high accuracy for detecting infection, while one surrogate virus neutralization test (sVNT) had slightly lower performance. The antibody kit targeting the receptor-binding domain (RBD) of the spike protein demonstrated the best correlation with neutralization titers, and measurement of antibodies for the nucleocapsid protein (NP) was less accurate in the convalescent phase.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Shuo Feng et al.
Summary: Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine were identified as correlates of protection against symptomatic infection. Higher levels of immune markers were correlated with a reduced risk of symptomatic infection. The data can be used to extrapolate efficacy estimates to new populations.
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: The study shows that receiving a booster dose of the BNT162b2 vaccine can significantly lower the rates of confirmed Covid-19 and severe illness, as well as reduce mortality among individuals aged 60 and above.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Ronen Arbel et al.
Summary: Among 843,208 participants in Israel aged 50 years or older who had received two doses of the BNT162b2 vaccine at least 5 months earlier, those who received a booster had 90% lower mortality due to Covid-19 than those who did not receive a booster during the 54-day study period.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Qian He et al.
Summary: Our study demonstrated that utilizing a heterologous prime-boost strategy with different combinations of COVID-19 vaccine candidates can enhance neutralizing antibody levels and T cell responses, providing new insights for vaccine development and application in controlling the SARS-CoV-2 pandemic.
EMERGING MICROBES & INFECTIONS
(2021)
Letter
Biotechnology & Applied Microbiology
Areti Tychala et al.
Summary: Vaccines against SARS-CoV-2 have shown varied immunogenicity among individuals, with some having lower levels of antibody production and others exhibiting notably high levels. The study found that participants with high antibody levels demonstrated adequate cellular response, while those with low antibody levels generally showed limited to absent cellular response five months post vaccination.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Letter
Immunology
Jens T. Van Praet et al.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Yushi Nomura et al.
Summary: The study found that the median antibody titer at six months after receiving the BNT162b2 vaccine was 539 U/mL. Age and smoking were identified as important factors affecting antibody titers, while sex was the only significant factor affecting the change in antibody titers from three to six months.
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Surgery
Tina Schmidt et al.
Summary: This study found that solid organ transplant recipients had lower levels of SARS-CoV-2-specific antibodies and T cells compared to controls after homologous or heterologous vaccination. However, heterologous vaccination showed promise in improving immune responses in transplant recipients, with higher induction of antibodies and CD4 T cells.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Infectious Diseases
Soumya Jaganathan et al.
Summary: This study evaluated total antibody and T cell responses in COVID-19 convalescents and vaccinated individuals, finding robust immune responses to SARS-CoV-2 mRNA vaccines in vaccinated subjects and sustained responses in convalescent donors for up to 1 year post-infection.
INFECTIOUS DISEASES AND THERAPY
(2021)
Article
Medicine, Research & Experimental
Sabra Klein et al.
JOURNAL OF CLINICAL INVESTIGATION
(2020)
Review
Multidisciplinary Sciences
Nathan Post et al.
